SEC Filings TLDR
Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.
Currently we only process 8-K, 6-K, Schedule 13G. We will support more forms in the future.
Filter by Form Type:
2025-10-28MSAIWSCHEDULE 13D/AMultiSensor AI Holdings, Inc. - Amendment to Schedule 13DMEDIUM
MultiSensor AI Holdings, Inc. filed an amendment to its Schedule 13D, disclosing changes in ownership and transactions related to its common stock. The amendment includes details about the acquisition of shares and warrants by 325 Capital Master Fund LP and other reporting persons. The transactions are part of a privat...
2025-10-28FHISCHEDULE 13DFederated Hermes, Inc. Acquires Significant Stake in Minerva Neurosciences, Inc.MEDIUM
Federated Hermes, Inc. (FHI) has filed a Schedule 13D with the SEC, disclosing its acquisition of a significant stake in Minerva Neurosciences, Inc. As of October 21, 2025, FHI holds 1,351,275 shares of Minerva's common stock, representing a 19.32% ownership stake. The shares were acquired for an aggregate purchase pri...
2025-10-28INDI8-Kindie Semiconductor, Inc. Enters into Asset Purchase Agreement for Wuxi indie MicroelectronicsM&A / divestitureHIGH
On October 27, 2025, indie Semiconductor, Inc. ("indie") entered into an Asset Purchase Agreement with United Faith Auto-Engineering Co., Ltd. ("United Faith") to sell its 34.38% equity interest in Wuxi indie Microelectronics Technology Co., Ltd. ("Wuxi") for approximately $135 million. The transaction is subject to cl...
2025-10-28DMYY8-KdMY Squared Technology Group, Inc. Extends Business Combination Deadlineoperation relatedMEDIUM
On October 27, 2025, dMY Squared Technology Group, Inc. (the 'Company') deposited an additional $50,000 into its trust account to extend the deadline for consummating an initial business combination. The extension moves the deadline from October 29, 2025, to November 29, 2025. This is the 22nd of 23 potential one-month...
2025-10-28BIAF8-KbioAffinity Technologies Announces Acceptance of Australian Patent Applicationoperation relatedMEDIUM
On October 28, 2025, bioAffinity Technologies, Inc. announced that the Australian Patent Office has accepted its patent application AU 2019253111 titled 'System and Method for Determining Lung Health.' This patent covers methods using flow cytometry combined with fluorescent probes to detect cellular and molecular sign...
2025-10-28ZWS8-KZurn Elkay Water Solutions Q3 2025 Earnings ReleaseearningsHIGH
Zurn Elkay Water Solutions Corporation reported its financial results for the third quarter ended September 30, 2025. The company achieved net sales of $455 million, an 11% increase compared to the same quarter in the previous year. Net income from continuing operations was $60 million, with diluted EPS from continuing...
2025-10-28ZTS8-KZoetis Appoints Stephanie Tilenius to Board of Directorsofficer / director changeMEDIUM
Zoetis Inc. announced the appointment of Stephanie Tilenius to its Board of Directors, effective December 1, 2025. Tilenius brings extensive experience in digital health and technology, having founded several healthcare companies, including Vida Health, Inc., and holding senior positions at Google, PayPal, and eBay. He...
2025-10-28ZDGE8-KZedge, Inc. Reports Fourth Quarter and Full Year Fiscal 2025 ResultsearningsMEDIUM
Zedge, Inc. announced its financial results for the fourth quarter and full fiscal year ended July 31, 2025. The company reported a 47% year-over-year increase in active subscriptions, reaching a record 984K, and a 21% growth in subscription revenue. ARPMAU (Average Revenue Per Monthly Active User) grew by 17% year-ove...
2025-10-28ZBRA8-KZebra Technologies Announces Third-Quarter 2025 ResultsearningsMEDIUM
Zebra Technologies Corporation reported its financial results for the third quarter ended September 27, 2025. The company achieved net sales of $1,320 million, a 5.2% increase year-over-year. Net income for the quarter was $101 million, or $1.97 per diluted share, compared to $137 million, or $2.64 per diluted share, i...
2025-10-28XYL8-KXylem Inc. Q3 2025 Earnings ReleaseearningsHIGH
Xylem Inc. reported its third-quarter 2025 financial results, showcasing strong performance with total revenue of $2.3 billion, an 8% increase on a reported basis and 7% organically. Earnings per share (EPS) were $0.93, up 4% on a reported basis, and $1.37 on an adjusted basis, reflecting a 23% increase. The company ra...
2025-10-28WNEB8-KWestern New England Bancorp Q3 2025 Earnings ReleaseearningsMEDIUM
Western New England Bancorp, Inc. reported its financial results for the quarter and nine months ended September 30, 2025. For the third quarter, the company posted net income of $3.2 million, or $0.16 per diluted share, compared to $1.9 million, or $0.09 per diluted share, in the same period last year. Total loans inc...
2025-10-28W8-KWayfair Q3 2025 Financial ResultsearningsMEDIUM
Wayfair Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported total net revenue of $3.1 billion, an 8.1% increase year over year. U.S. net revenue grew by 8.6% to $2.7 billion, while international net revenue increased by 4.6% to $389 million. Gross profit was $934 mi...
2025-10-28WKC8-KWorld Kinect Corporation Announces Key Leadership Changes and Board Appointmentofficer / director changeMEDIUM
World Kinect Corporation reported significant leadership changes and a new board appointment in its 8-K filing dated October 22, 2025. The Board of Directors appointed Andrea B. Smith as a new director, effective October 24, 2025, increasing the board size from 10 to 11 members. Smith will serve on the Compensation and...
2025-10-28WELL8-KWelltower Inc. Announces $7.5 Billion At-The-Market Equity Offeringequity offeringHIGH
Welltower Inc. has entered into an equity distribution agreement to offer and sell shares of its common stock with an aggregate sales price of up to $7.5 billion. The shares may be sold through various sales agents and forward sellers, including BofA Securities, Inc., Goldman Sachs & Co. LLC, and J.P. Morgan Securities...
2025-10-28WPC8-KW. P. Carey Inc. Q3 2025 Earnings ReleaseearningsHIGH
W. P. Carey Inc. reported its financial results for the third quarter ended September 30, 2025. The company announced a net income of $141.0 million, or $0.64 per diluted share, and Adjusted Funds from Operations (AFFO) of $276.6 million, or $1.25 per diluted share. The company raised and narrowed its 2025 AFFO guidanc...
2025-10-28VOR8-KVor Biopharma Inc. 48-week Phase 3 Clinical Trial Data for Telitacicept in Primary Sjögren’s Diseaseoperation relatedHIGH
Vor Biopharma Inc. reported the results of a 48-week Phase 3 clinical trial for telitacicept in primary Sjögren’s disease. The trial, conducted in China, demonstrated statistically significant and clinically meaningful improvements in both physician-assessed and patient-reported outcomes. The primary endpoint was the c...
2025-10-28VANI8-KVivani Medical, Inc. Announces Private Placement and Registered Direct Offeringequity offeringMEDIUM
Vivani Medical, Inc. entered into a Share Purchase Agreement on October 26, 2025, with an entity affiliated with Gregg Williams, Chairman of the Company’s board of directors, for the purchase of 3,703,703 shares of common stock at $1.62 per share, resulting in gross proceeds of approximately $6.0 million. Concurrently,...
2025-10-28VST8-KVistra Corp. Completes Acquisition of Seven Natural Gas PlantsM&A / divestitureHIGH
On October 22, 2025, Vistra Corp. announced the completion of its acquisition of seven natural gas generation facilities from Lotus Infrastructure Partners. The acquisition, totaling approximately 2,600 MW of capacity, was finalized after receiving all necessary regulatory approvals. The transaction, valued at a base p...
2025-10-28VLTO8-KVeralto Corporation Q3 2025 Earnings ReleaseearningsHIGH
Veralto Corporation announced its financial results for the third quarter ended October 3, 2025. The company reported a 6.9% year-over-year increase in sales, reaching $1,404 million, with non-GAAP core sales growth of 5.1%. Operating profit margin stood at 23.2%, while non-GAAP adjusted operating profit margin was 23....
2025-10-28VSEEW8-KVSee Health, Inc. Announces 2025 Annual Meeting Detailsshareholder relatedMEDIUM
VSee Health, Inc. has announced the details for its 2025 Annual Meeting of Stockholders. The meeting is scheduled to take place on December 15, 2025, with the record date for determining eligible stockholders set as November 20, 2025. The company has established a deadline of November 7, 2025, for receiving stockholder...
2025-10-28V8-KVisa Inc. Fiscal Fourth Quarter and Full-Year 2025 Earnings ReleaseearningsHIGH
Visa Inc. reported its fiscal fourth quarter and full-year 2025 financial results. For the fourth quarter, the company achieved a GAAP net income of $5.1 billion, or $2.62 per share, and non-GAAP net income of $5.8 billion, or $2.98 per share. Net revenue for the quarter was $10.7 billion, a 12% increase year-over-year...
2025-10-28VRNS8-KVaronis Systems Q3 2025 Financial ResultsearningsMEDIUM
Varonis Systems, Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported total revenues of $161.6 million, an increase from $148.1 million in the same quarter of the previous year. SaaS revenues were $125.8 million, up significantly from $57.8 million in Q3 2024. Howeve...
2025-10-28VFC8-KV.F. Corporation Q2 Fiscal 2026 Earnings ReleaseearningsHIGH
V.F. Corporation reported its financial results for the second quarter of Fiscal 2026, ending September 27, 2025. The company announced a quarterly dividend of $0.09 per share. Revenue for the quarter was $2.8 billion, a 2% increase year-over-year (YoY) or a 1% decrease on a constant currency basis. The North Face® and...
2025-10-28PRKS8-KResignation and Appointment of Chief Financial Officer at United Parks & Resorts Inc.officer / director changeMEDIUM
On October 22, 2025, James Mikolaichik resigned from his position as Chief Financial Officer and Treasurer of United Parks & Resorts Inc., effective November 15, 2025. His resignation was not due to any disagreements with the company regarding financial statements, internal controls, operations, policies, or practices....
2025-10-28UNCY8-KUnicycive Therapeutics Provides Update on FDA Meeting and NDA Resubmissionregulatory investigationMEDIUM
Unicycive Therapeutics, Inc. announced an update from its meeting with the U.S. Food and Drug Administration (FDA) regarding the resubmission of its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC). The company plans to resubmit the NDA by the end of 2025, following the resolution of a manufacturing complian...